DARZALEX — Sales to customers (Note 9)
Johnson & Johnson DARZALEX — Sales to customers (Note 9) increased by 1.6% to $3.96B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.5%, from $3.24B to $3.96B. Over 4 years (FY 2021 to FY 2025), DARZALEX — Sales to customers (Note 9) shows an upward trend with a 24.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market penetration and clinical demand for the therapy, while a decrease may signal increased competition, patent expiration, or shifts in treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific high-growth oncology therapeutic prod...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or key therapeutic assets reported by other major pharmaceutical companies.
jnj_segment_darzalex_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.43B | $1.58B | $1.65B | $1.86B | $1.99B | $2.05B | $2.08B | $2.26B | $2.43B | $2.50B | $2.55B | $2.69B | $2.88B | $3.02B | $3.08B | $3.24B | $3.54B | $3.67B | $3.90B | $3.96B |
| QoQ Change | — | +10.3% | +4.1% | +12.8% | +7.0% | +3.3% | +1.5% | +8.7% | +7.4% | +2.8% | +2.0% | +5.6% | +6.9% | +4.8% | +2.3% | +5.0% | +9.3% | +3.8% | +6.3% | +1.6% |
| YoY Change | — | — | — | — | +38.6% | +29.9% | +26.6% | +22.0% | +22.4% | +21.8% | +22.4% | +18.9% | +18.4% | +20.7% | +20.9% | +20.2% | +23.0% | +21.8% | +26.6% | +22.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's darzalex — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported darzalex — sales to customers (note 9) of $3.96B in Q1 2026.
- How has Johnson & Johnson's darzalex — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's darzalex — sales to customers (note 9) increased by 22.5% year-over-year, from $3.24B to $3.96B.
- What is the long-term trend for Johnson & Johnson's darzalex — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's darzalex — sales to customers (note 9) has grown at a 24.2% compound annual growth rate (CAGR), from $6.02B to $14.35B.
- What does darzalex — sales to customers (note 9) mean?
- The total revenue earned from sales of a specific oncology drug product.